Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Global Phase III Trial of LUBT010 vs Lucentis in Neovascular Age-Related Macular Degeneration
2017-004409-42Phase 3Completed
- Sponsor
- Lupin Limited
- Start
- Oct 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of LUBT010 in exudative macular degeneration (2 arms), sponsored by Lupin Limited. Primary endpoint: Change in BCVA at 12 months. Started Oct 2020; status: completed.
02
Drugs
LUBT010
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2017-004409-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004409-42.